[Drugs, Parkinson's disease and parkinsonian syndroms: recent advances in pharmacovigilance].
Identifieur interne : 000E71 ( PubMed/Curation ); précédent : 000E70; suivant : 000E72[Drugs, Parkinson's disease and parkinsonian syndroms: recent advances in pharmacovigilance].
Auteurs : Jean-Louis Montastruc [France] ; Agnès Sommet ; Pascale Olivier ; Haleh Bagheri ; Mireille Gony ; Maryse Lapeyre-Mestre ; Christine Brefel-Courbon ; Joachim Ferreira ; Laurent Schmitt ; Jean-Michel Senard ; Olivier RascolSource :
- Therapie [ 0040-5957 ]
Descripteurs français
- Wicri :
- geographic : France.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Dopamine Agonists.
- geographic : France.
- drug therapy : Parkinson Disease, Parkinsonian Disorders.
- standards : Drug Prescriptions.
- statistics & numerical data : Accidents, Traffic.
- Humans.
Abstract
This paper reviews recent data on the pharmacovigilance of antiparkinsonian drugs and drugs inducing parkinsonian syndroms. Sudden sleep attacks were first described in 1999 with dopamine agonists. In fact, they can be induced by all the dopaminergic antiparkinsonian drugs. Favorising factors are duration of the disease, dose of dopaminergic drugs, daytime somnolence or dysautonomia. This adverse drug reaction can be serious leading, for example, to road accidents. Cardiac valvulopathies were more recently (end of 2002) described with pergolide. Thus, this dopamine agonist should now be prescribed as a last choice among dopamine agonists. Dopamine drugs (levodopa as well as dopamine agonists) can induce hypersexual behaviours or pathological gambling. Among the long list of drugs inducing parkinsonian syndroms, recent data suggest the involvement of serotoninergic antidepressants, valproic acid and trimetazidine. Finally, these data on pharmacovigilance allow to precise the physiological role of dopamine: beside its motor and psychic effects, dopamine is also involved in the sleep-arousal control. It is also an important mediator for pleasure, hedonic regulations and sexual behaviour. This review also underlines the major role of spontaneous reports to the pharmacovigilance systems to identify new adverse drug reactions.
PubMed: 16792152
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000F11
Links to Exploration step
pubmed:16792152Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Drugs, Parkinson's disease and parkinsonian syndroms: recent advances in pharmacovigilance].</title><author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire de Pharmacologie Médicale et Clinique, Unité de Pharmacoépidémiologie, UA 3696, IFR 126, Université Paul Sabatier, Faculté de Médecine, Toulouse, France. montastruc@cict.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Pharmacologie Médicale et Clinique, Unité de Pharmacoépidémiologie, UA 3696, IFR 126, Université Paul Sabatier, Faculté de Médecine, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Sommet, Agnes" sort="Sommet, Agnes" uniqKey="Sommet A" first="Agnès" last="Sommet">Agnès Sommet</name></author><author><name sortKey="Olivier, Pascale" sort="Olivier, Pascale" uniqKey="Olivier P" first="Pascale" last="Olivier">Pascale Olivier</name></author><author><name sortKey="Bagheri, Haleh" sort="Bagheri, Haleh" uniqKey="Bagheri H" first="Haleh" last="Bagheri">Haleh Bagheri</name></author><author><name sortKey="Gony, Mireille" sort="Gony, Mireille" uniqKey="Gony M" first="Mireille" last="Gony">Mireille Gony</name></author><author><name sortKey="Lapeyre Mestre, Maryse" sort="Lapeyre Mestre, Maryse" uniqKey="Lapeyre Mestre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name></author><author><name sortKey="Brefel Courbon, Christine" sort="Brefel Courbon, Christine" uniqKey="Brefel Courbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name></author><author><name sortKey="Ferreira, Joachim" sort="Ferreira, Joachim" uniqKey="Ferreira J" first="Joachim" last="Ferreira">Joachim Ferreira</name></author><author><name sortKey="Schmitt, Laurent" sort="Schmitt, Laurent" uniqKey="Schmitt L" first="Laurent" last="Schmitt">Laurent Schmitt</name></author><author><name sortKey="Senard, Jean Michel" sort="Senard, Jean Michel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>2006 Jan-Feb</MedlineDate></PubDate></date><idno type="RBID">pubmed:16792152</idno><idno type="pmid">16792152</idno><idno type="wicri:Area/PubMed/Corpus">000F11</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F11</idno><idno type="wicri:Area/PubMed/Curation">000E71</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000E71</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Drugs, Parkinson's disease and parkinsonian syndroms: recent advances in pharmacovigilance].</title><author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire de Pharmacologie Médicale et Clinique, Unité de Pharmacoépidémiologie, UA 3696, IFR 126, Université Paul Sabatier, Faculté de Médecine, Toulouse, France. montastruc@cict.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Pharmacologie Médicale et Clinique, Unité de Pharmacoépidémiologie, UA 3696, IFR 126, Université Paul Sabatier, Faculté de Médecine, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Sommet, Agnes" sort="Sommet, Agnes" uniqKey="Sommet A" first="Agnès" last="Sommet">Agnès Sommet</name></author><author><name sortKey="Olivier, Pascale" sort="Olivier, Pascale" uniqKey="Olivier P" first="Pascale" last="Olivier">Pascale Olivier</name></author><author><name sortKey="Bagheri, Haleh" sort="Bagheri, Haleh" uniqKey="Bagheri H" first="Haleh" last="Bagheri">Haleh Bagheri</name></author><author><name sortKey="Gony, Mireille" sort="Gony, Mireille" uniqKey="Gony M" first="Mireille" last="Gony">Mireille Gony</name></author><author><name sortKey="Lapeyre Mestre, Maryse" sort="Lapeyre Mestre, Maryse" uniqKey="Lapeyre Mestre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name></author><author><name sortKey="Brefel Courbon, Christine" sort="Brefel Courbon, Christine" uniqKey="Brefel Courbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name></author><author><name sortKey="Ferreira, Joachim" sort="Ferreira, Joachim" uniqKey="Ferreira J" first="Joachim" last="Ferreira">Joachim Ferreira</name></author><author><name sortKey="Schmitt, Laurent" sort="Schmitt, Laurent" uniqKey="Schmitt L" first="Laurent" last="Schmitt">Laurent Schmitt</name></author><author><name sortKey="Senard, Jean Michel" sort="Senard, Jean Michel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></author></analytic><series><title level="j">Therapie</title><idno type="ISSN">0040-5957</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Accidents, Traffic (statistics & numerical data)</term><term>Antiparkinson Agents (adverse effects)</term><term>Dopamine Agonists (adverse effects)</term><term>Drug Prescriptions (standards)</term><term>France</term><term>Humans</term><term>Parkinson Disease (drug therapy)</term><term>Parkinsonian Disorders (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agonists</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>France</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Drug Prescriptions</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Accidents, Traffic</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>France</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This paper reviews recent data on the pharmacovigilance of antiparkinsonian drugs and drugs inducing parkinsonian syndroms. Sudden sleep attacks were first described in 1999 with dopamine agonists. In fact, they can be induced by all the dopaminergic antiparkinsonian drugs. Favorising factors are duration of the disease, dose of dopaminergic drugs, daytime somnolence or dysautonomia. This adverse drug reaction can be serious leading, for example, to road accidents. Cardiac valvulopathies were more recently (end of 2002) described with pergolide. Thus, this dopamine agonist should now be prescribed as a last choice among dopamine agonists. Dopamine drugs (levodopa as well as dopamine agonists) can induce hypersexual behaviours or pathological gambling. Among the long list of drugs inducing parkinsonian syndroms, recent data suggest the involvement of serotoninergic antidepressants, valproic acid and trimetazidine. Finally, these data on pharmacovigilance allow to precise the physiological role of dopamine: beside its motor and psychic effects, dopamine is also involved in the sleep-arousal control. It is also an important mediator for pleasure, hedonic regulations and sexual behaviour. This review also underlines the major role of spontaneous reports to the pharmacovigilance systems to identify new adverse drug reactions.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16792152</PMID><DateCreated><Year>2006</Year><Month>06</Month><Day>23</Day></DateCreated><DateCompleted><Year>2006</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2008</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0040-5957</ISSN><JournalIssue CitedMedium="Print"><Volume>61</Volume><Issue>1</Issue><PubDate><MedlineDate>2006 Jan-Feb</MedlineDate></PubDate></JournalIssue><Title>Therapie</Title><ISOAbbreviation>Therapie</ISOAbbreviation></Journal><ArticleTitle>[Drugs, Parkinson's disease and parkinsonian syndroms: recent advances in pharmacovigilance].</ArticleTitle><Pagination><MedlinePgn>29-38</MedlinePgn></Pagination><Abstract><AbstractText>This paper reviews recent data on the pharmacovigilance of antiparkinsonian drugs and drugs inducing parkinsonian syndroms. Sudden sleep attacks were first described in 1999 with dopamine agonists. In fact, they can be induced by all the dopaminergic antiparkinsonian drugs. Favorising factors are duration of the disease, dose of dopaminergic drugs, daytime somnolence or dysautonomia. This adverse drug reaction can be serious leading, for example, to road accidents. Cardiac valvulopathies were more recently (end of 2002) described with pergolide. Thus, this dopamine agonist should now be prescribed as a last choice among dopamine agonists. Dopamine drugs (levodopa as well as dopamine agonists) can induce hypersexual behaviours or pathological gambling. Among the long list of drugs inducing parkinsonian syndroms, recent data suggest the involvement of serotoninergic antidepressants, valproic acid and trimetazidine. Finally, these data on pharmacovigilance allow to precise the physiological role of dopamine: beside its motor and psychic effects, dopamine is also involved in the sleep-arousal control. It is also an important mediator for pleasure, hedonic regulations and sexual behaviour. This review also underlines the major role of spontaneous reports to the pharmacovigilance systems to identify new adverse drug reactions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Montastruc</LastName><ForeName>Jean-Louis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Laboratoire de Pharmacologie Médicale et Clinique, Unité de Pharmacoépidémiologie, UA 3696, IFR 126, Université Paul Sabatier, Faculté de Médecine, Toulouse, France. montastruc@cict.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sommet</LastName><ForeName>Agnès</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Olivier</LastName><ForeName>Pascale</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Bagheri</LastName><ForeName>Haleh</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Gony</LastName><ForeName>Mireille</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lapeyre-Mestre</LastName><ForeName>Maryse</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Brefel-Courbon</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Joachim</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Schmitt</LastName><ForeName>Laurent</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Senard</LastName><ForeName>Jean-Michel</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Rascol</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Medicaments, maladie de Parkinson et syndromes parkinsoniens: actualités de pharmacovigilance.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Therapie</MedlineTA><NlmUniqueID>0420544</NlmUniqueID><ISSNLinking>0040-5957</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000063" MajorTopicYN="N">Accidents, Traffic</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011307" MajorTopicYN="N">Drug Prescriptions</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="N">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>6</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>6</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16792152</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E71 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000E71 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:16792152
|texte= [Drugs, Parkinson's disease and parkinsonian syndroms: recent advances in pharmacovigilance].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:16792152" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |